Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
3.000
+0.070 (2.39%)
Dec 20, 2024, 4:00 PM EST - Market closed
Zentalis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 40.56 | - | - | - | - | - | Upgrade
|
| Gross Profit | 40.56 | - | - | - | - | - | Upgrade
|
| Selling, General & Admin | 63.48 | 59.4 | 54.55 | 40.94 | 33.89 | 8.46 | Upgrade
|
| Research & Development | 186.35 | 189.59 | 172.73 | 166.8 | 84.9 | 38.39 | Upgrade
|
| Operating Expenses | 249.83 | 248.99 | 227.29 | 207.74 | 118.79 | 46.85 | Upgrade
|
| Operating Income | -209.27 | -248.99 | -227.29 | -207.74 | -118.79 | -46.85 | Upgrade
|
| Interest & Investment Income | 11.1 | 9.46 | 2.26 | 1.31 | 1.24 | 0.48 | Upgrade
|
| Earnings From Equity Investments | - | -16.01 | -16.28 | -1.83 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -198.17 | -255.54 | -241.31 | -208.26 | -117.55 | -46.36 | Upgrade
|
| Gain (Loss) on Sale of Investments | 19.08 | 13.16 | 3.73 | -0.91 | -0.56 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 51.58 | - | - | Upgrade
|
| Asset Writedown | - | -4.95 | - | -8.8 | - | - | Upgrade
|
| Pretax Income | -179.09 | -292.91 | -237.58 | -166.39 | -118.1 | -46.36 | Upgrade
|
| Income Tax Expense | 0.25 | -0.6 | -0.47 | -0.3 | 0.44 | 0.02 | Upgrade
|
| Earnings From Continuing Operations | -179.33 | -292.31 | -237.11 | -166.09 | -118.55 | -46.38 | Upgrade
|
| Minority Interest in Earnings | 0.05 | 0.11 | 0.31 | 7.37 | 0.71 | 0.72 | Upgrade
|
| Net Income | -179.28 | -292.19 | -236.81 | -158.73 | -117.84 | -45.66 | Upgrade
|
| Net Income to Common | -179.28 | -292.19 | -236.81 | -158.73 | -117.84 | -45.66 | Upgrade
|
| Shares Outstanding (Basic) | 71 | 65 | 53 | 43 | 28 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 71 | 65 | 53 | 43 | 28 | 6 | Upgrade
|
| Shares Change (YoY) | 14.04% | 23.75% | 23.82% | 51.84% | 402.29% | 0.05% | Upgrade
|
| EPS (Basic) | -2.53 | -4.47 | -4.48 | -3.72 | -4.19 | -8.16 | Upgrade
|
| EPS (Diluted) | -2.53 | -4.47 | -4.48 | -3.72 | -4.19 | -8.16 | Upgrade
|
| Free Cash Flow | -172.15 | -208.41 | -166.3 | -160.2 | -87.58 | -39.5 | Upgrade
|
| Free Cash Flow Per Share | -2.43 | -3.19 | -3.15 | -3.75 | -3.12 | -7.06 | Upgrade
|
| Gross Margin | 100.00% | - | - | - | - | - | Upgrade
|
| Operating Margin | -515.94% | - | - | - | - | - | Upgrade
|
| Profit Margin | -442.02% | - | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -424.44% | - | - | - | - | - | Upgrade
|
| EBITDA | -207.96 | -247.6 | -225.86 | -207.2 | -118.63 | -46.73 | Upgrade
|
| D&A For EBITDA | 1.31 | 1.39 | 1.43 | 0.54 | 0.16 | 0.11 | Upgrade
|
| EBIT | -209.27 | -248.99 | -227.29 | -207.74 | -118.79 | -46.85 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.